ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer CenterNew data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).